Par Pharmaceutical Companies (PRX)
Par Pharmaceutical Companies SG&A Expense: 42.16M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRX SG&A Expense Rankings
| Overall | 38th percentile | 2582 of 4190 |
| Sector | 25th percentile | 362 of 485 in Healthcare |
| Industry | 28th percentile | 10 of 14 in Drugs - Generic |
PRX SG&A Expense Range, Past 5 Years
| Minimum | 30.66M | Sep 2008 |
| Maximum | 52.10M | Dec 2010 |
| Average | 40.84M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these PRX related companies
PRX News
RT @TraderRadar $AAPL $NFLX $PRX Keep these on your radar for higher prices next week// $NFLX based on what evidence??
about a day ago by lipong23
about a day ago by lipong23
$AAPL $NFLX $PRX Keep these on your radar for higher prices next week
about a day ago by TraderRadar
about a day ago by TraderRadar
@TraderRadar Like $PRX - should keep moving after pull back to $39 area
about a day ago by OMillionaires
about a day ago by OMillionaires
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call
May 09, 12:21PM Street Insider
May 09, 12:21PM Street Insider
Listen to $PRX Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3iVK
about 18 days ago by earningscast
about 18 days ago by earningscast
Also sold my $HMSY on weakness. Picked up shares of $PRX Friday. Any thoughts?
about 35 days ago by robertfreedland
about 35 days ago by robertfreedland
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Healthy Deal with Handa
Apr 20, 9:46AM Street Insider
Apr 20, 9:46AM Street Insider
Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S.
Apr 19, 3:05PM Benzinga
Apr 19, 3:05PM Benzinga
Par Pharmaceutical Companies to Report First Quarter 2012 Results on May 8, 2012
Apr 09, 9:00AM PR Newswire
Apr 09, 9:00AM PR Newswire
$PRX is 5.0% up since open on unusual high volume and 5.5% up since close.
about 51 days ago by TradeBot
about 51 days ago by TradeBot
$WCG $CL $SJM $PRX Hit 52-Week Highs http://stks.co/39sz My story via @TheStreet #52WeekHigh
about 57 days ago by azendrian
about 57 days ago by azendrian
$PRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/39RA
about 57 days ago by MarketBrief
about 57 days ago by MarketBrief
Horizon Pharma (HZNP) Files Patent Infringement Suit Against Par Pharma (PRX) Over DUEXIS Tabs
Mar 28, 4:30PM Street Insider
Mar 28, 4:30PM Street Insider
$PRX forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/33Pn
about 64 days ago by RecogniaEvents
about 64 days ago by RecogniaEvents
Impressive development programs, partnerships and product launch prep make IntelGenX look like a solid bet at these prices
Mar 23, 8:34AM Thomson Reuters ONE
Mar 23, 8:34AM Thomson Reuters ONE
$PRX forms bearish "Triple Top" chart pattern. http://stks.co/2epQ
about 85 days ago by RecogniaEvents
about 85 days ago by RecogniaEvents
Listen to $PRX Q4 2011 earnings call - live at 09:00 AM, ondemand after - http://stks.co/2af5
about 88 days ago by earningscast
about 88 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRX | 40.88 | +1.34 | +3.39% | 1.495B |
| PRU | 47.20 | -0.13 | -0.27% | 22.17B |
| PRST | 0.56 | +0.01 | +1.82% | 20.93M |
| PRO | 15.83 | +0.04 | +0.25% | 429.15M |
| PRLS | 3.78 | +0.00 | +0.00% | 13.38M |
| PRGO | 103.00 | +0.08 | +0.08% | 9.610B |
| PRGN | 0.58 | +0.00 | +0.83% | 34.72M |
| PRFT | 11.57 | +0.10 | +0.87% | 361.79M |
| PRF | 56.28 | -0.01 | -0.02% | |
| PRE | 72.31 | +0.30 | +0.42% | 4.728B |
